Cancer Diagnostics Market

Cancer Diagnostics Industry | Forecast 2030

The global cancer diagnostics market is combine to account for USD 45.66 billion revenue in 2022, which is expected to reach USD 89.02 billion by 2030, growing at a cumulative rate of 5.97% over the forecast period. The combination bundle is designed to provide a holistic view of these highly dynamic market spaces.

Breast Cancer Diagnostics Market Insights

The global breast cancer diagnostics market size was valued at USD 4.3 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 7.4% from 2023 to 2030. The market is anticipated to witness growth due to the rising incidence of breast cancer, which is recognized as one of the most prevalent cancers worldwide. According to the American Cancer Society, it is estimated that approximately 281,550 new cases of breast cancer will be diagnosed in 2021, with an expected 49,290 related deaths in the U.S. alone. Globally, breast cancer has been identified by the WHO as the most common type of cancer, with new cases surpassing 2.3 million in 2021. These statistics highlight the urgent need for advanced breast cancer diagnostic solutions to facilitate early detection, accurate prognosis, and effective treatment strategies.

Access the Global Cancer Diagnostics Industry Data Book, 2023 to 2030, compiled with details like market sizing information & forecasts, trade data, pricing intelligence, competitive benchmarking, macro-environmental analyses, and regulatory & technological framework studies

Cervical Cancer Diagnostic Market Insights

The global cervical cancer diagnostic market size was valued at USD 4.5 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 5.7% from 2023 to 2030. The increasing prevalence of cervical cancer in middle-aged women and the subsequent increase in screening and diagnostic tests are expected to boost the market over the forecast period. As per the reports published by World Health Organization, cervical cancer is the fourth most common cancer among women globally. Furthermore, according to a statistics report published by the American Cancer Society, in 2023, about 13,960 estimated cases of invasive cervical cancer will be diagnosed, with around 4,310 women deaths in the U.S.

Lung Cancer Diagnostics Market Insights

The global lung cancer diagnostics market size was estimated at USD 1.63 billion in 2015. Technological advancements pertaining to tumor diagnosis contribute to market growth. The need for more efficient diagnostic systems is due to the fact that only 15% of the lung cancer cases get diagnosed while the remaining undiagnosed cancer cases develop into more aggressive forms, which reduces the 5-year survival rate to only 4% in these patients that are detected with late-stage lung cancer.

In the developing world, there has been a dramatic rise in the prevalence of smoking, which is expected to influence the incidence rate of lung malignancies in the coming years. The increasing prevalence of cancer is directly proportional to market growth as it propels the demand for early screening and diagnosis of cancer.

Liver Cancer Diagnostics Market Insights

The global liver cancer diagnostics market size was valued at USD 8,718.8 million in 2022 and is anticipated to expand at a compound annual growth rate (CAGR) of 6.67% by 2030. Around the world, liver cancer is among the leading cause of cancer-related deaths. As per the American Cancer Society, since the 1980s, liver cancer occurrence rates have increased three times and death rates have doubled now. According to cancer statistics in 2022, in the U.S., around 41,260 new cases are expected to be diagnosed whereas about 30,520 deaths will account because of liver cancer. The prevalence of liver cancer worldwide and the associated continuous exposure of the population to risk factors will drive the screening & diagnosis market rapidly.

Order your copy of the Free Sample of “Cancer Diagnostics Industry Data Book – Breast Cancer Diagnostic, Cervical Cancer Diagnostic, Lung Cancer Diagnostic, Liver Cancer Diagnostic, Pancreatic Cancer Diagnostic and Ovarian Cancer Diagnostic Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 – 2030” Data Book, published by Grand View Research

Pancreatic Cancer Diagnostic Market Insights

The global pancreatic cancer diagnostic market size was valued at USD 2.37 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 6.53% from 2023 to 2030. The increasing prevalence of pancreatic cancer and the rise in awareness regarding early disease diagnosis is the leading factor driving the global market. In addition, technological advancements in terms of accuracy & sensitivity of diagnostic tests, evolution in molecular diagnostics, and biomarker tests used for malignancy detection are other factors propelling the market demand forward.

Key Players:

GE Healthcare, Abbott, F. Hoffmann-La Roche Ltd.,, QIAGEN, BD, Siemens Healthcare GmbH,, Thermo Fisher Scientific; Inc., Hologic, Inc., Koninklijke Philips N.V. (Philips), IIumina, inc.

Cancer Diagnostics Industry | Forecast 2030

Cancer Diagnostics Industry Data Book – Breast Cancer Diagnostic, Cervical Cancer Diagnostic, Lung Cancer Diagnostic, Liver Cancer Diagnostic, Pancreatic Cancer Diagnostic and Ovarian Cancer Diagnostic Market

Cancer Diagnostics Industry Data Book Coverage Snapshot

Markets Covered

Cancer Diagnostics Industry USD 45.66 billion in 2022 5.9% CAGR (2023-2030)
Breast Cancer Diagnostic Market Size USD 16.26 billion in 2022 7.24% CAGR (2023-2030)
Cervical Cancer Diagnostic Market Size USD 4.55 billion in 2022 5.65% CAGR (2023-2030)
Lung Cancer Diagnostic Market Size USD 10.82 billion in 2022 7.59% CAGR (2023-2030)
Liver Cancer Diagnostic Market Size USD 5.99 billion in 2022 5.96% CAGR (2023-2030)
Pancreatic Cancer Diagnostic Market Size USD 3.63 billion in 2022 5.43% CAGR (2023-2030)
Ovarian Cancer Diagnostic Market Size USD 4.41 billion in 2022 4.93% CAGR (2023-2030)

Breast Cancer Diagnostics Market Growth & Trends

The global breast cancer diagnostics market size is expected to reach USD 7.7 billion by 2030, according to a new study by Grand View Research Inc. The market is expected to expand at a CAGR of 7.4% from 2023 to 2030. The growth is largely attributable to the increasing geriatric population exposed to the risk of breast cancer and early detection coupled with increasing awareness about breast cancer.

The introduction of 3D mammography or digital breast tomosynthesis, which is more accurate than 2D mammography, supports market growth. This advanced technology can detect 40.0% more cancers than 2D mammograms and reduce patient recalls. Rapid technological advancements are a major factor expected to drive the market over the coming years.

Companies are adopting strategies that allow them to use their resources to aid in the development of new products, as well as enhance their supply chain. In November 2019, Exact Sciences Corporation announced the acquisition of Genomic Health, which was expected to help enhance the company’s market position and offerings by acquiring its product portfolio. In January 2021, Hologic Inc. announced that it has agreed to acquire Biotheranostics for approximately US$ 230 million. Biotheranostics is a commercial-stage molecular diagnostics provider for breast and metastatic cancers.

Cervical Cancer Diagnostic Market Growth & Trends

The global cervical cancer diagnostic market size is expected to reach USD 7.0 billion by 2030, growing at a CAGR of 5.7% from 2023 to 2030, according to a new study conducted by Grand View Research, Inc. The key driving factors include the rising prevalence of cervical cancer, evolving screening technology, and various programs that promote routine check up and screening. According to the data published by the WHO, in 2012, over 270,000 women died due to cervical cancer, majority of which were from the developing countries. It is one of the most common cancer type diagnosed in women. Some of the etiological factors are multiple sex partners, and changing lifestyle, such as drinking & smoking and increased stress levels.

Furthermore, favorable government initiatives and increasing number of awareness programs are further expected to promote the market growth in coming few years. The National Cervical Cancer Coalition, WHO, CDC, the U.S. Preventive Services Task Force, are working towards promoting the necessity for early screening of cervical cancer amongst mid aged women.

Lung Cancer Diagnostics Market Growth & Trends

The global lung cancer diagnostics market is expected to reach USD 3,644.6 million by 2024, according to a new report by Grand View Research Inc. The development of lung cancer-specific biomarkers is one of the primary factors for the growth of the lung cancer diagnostics market over the forecast period. These diagnostic tools facilitate the personalized treatment approach of lung malignancies.

Various biomarkers are present in the research pipeline. For instance, in November 2015, Epigenomics AG announced the launch of a new blood-based test using DNA methylation biomarkers, the development of which is underway. The initial results of this test revealed a promising outcome in the early diagnosis of lung cancer.

Furthermore, various awareness programs focusing on lung cancer and its associated symptoms are initiated in an attempt to elevate the screening and diagnosis rates inindividuals at a high risk of developing lung malignancies. For instance, November is considered as a lung cancer awareness month across the UK, which is supported by the Roy Castle Lung Cancer Foundation.